There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: A population-based case-control study

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 11-12, 2010, Pages 1383-1391

  Dall, M ^a,b   Schaffalitzky De Muckadell, O B ^b   Lassen, A T ^b   Hallas, J ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG USE; DUODENUM ULCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ULCER;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIC ULCER; RISK FACTORS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 78449289498     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04472.x     Document Type: Article

References (38)

1. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J,. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7: 1314 - 21.
2. De Abajo FJ, Garcia Rodriguez LA, Montero D,. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: a population-based case-control study. Br Med J 1999; 319: 1106 - 9.
3. Van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655 8.
4. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59 - 64.
5. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22: 175 - 81.
6. Helin-Salmivaara A, Huttunen T, Grönroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. Eur J Clin Pharmacol 2007; 63: 403 - 8.
7. Opatrny L, Delaney JA, Suissa S,. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76 - 81.
8. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328 - 35.
9. De Abajo FJ, García-Rodríguez LA,. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795 - 803.
10. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475 - 82.
11. Dunn NR, Pearce GL, Shakir SA,. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ 2000; 320: 1405 - 6.
12. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937 - 44.
13. Vidal X, Ibáñez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31: 159 - 68.
14. Li N, Wallen NH, Ladjevardi M, Hjemdahl P,. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517 - 23.
15. Skop BP, Brown TM,. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12 - 6.
16. Javors MA, Houston JP, Tekell JL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3: 229 - 35.
17. Gaist D, Sørensen HT, Hallas J,. The Danish Prescription Registries. Dan Med Bull 1997; 44: 445 - 8.
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index With DDDs and Guidelines for ATC Classification and DDD Assignment. Oslo: Norwegian Institute of Public Health, 2006.
19. Frank L,. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398 - 9.
20. Rothman K,. Epidemiology: An Introduction. Oxford: Oxford University Press, 2002; 87.
21. Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA,. Towards a true prevalence of peptic ulcer: the Sørreisa gastrointestinal disorder study. Gut 1990; 31: 989 - 92.
22. Rosholm J-U, Andersen M, Gram LF,. Are there differences in the use of seelctive serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 2001; 56: 923 - 9.
23. Lassen A, Hallas J, Schaffalitzky de Muckadell OB,. Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study. BMJ 2003; 327: 603.
24. Bjerre LM, LeLorier J,. Expressing the magnitude of adverse effects in case-control studies. BMJ 2000; 320: 503 - 6.
25. StataCorp. Release 10.1. StataCorp, 4905 Lakeway Drive, College Station, Texas 77845, USA. Available at:. Accessed September 15, 2010.
26. Rothman K,. Epidemiology: An Introduction. Oxford: Oxford University Press, 2002; 100.
27. Rothman K,. Episheet, Spreadsheets for the Analysis of Epidemiologic Data. June 11, 2008.
28. Bak S, Tsiropoulos I, Kjarsgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: A population based case-control study. Stroke 2002; 33: 1465 - 73.
29. Kurata JH, Nogawa AN,. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2 - 17.
30. Adami H-O, Bergström R, Nyren O, et al. Is duodenal ulcer really a psychosomatic disease? A population-based case-control study. Scand J Gastroenterol 1987; 22: 889 - 96.
31. Friedman GD, Siegelaub AB, Seltzer CC,. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med 1974; 290: 469 - 73.
32. Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 1999; 94: 3189 - 96.
33. Available at:. Accessed December 7, 2009.
34. Wallace JL, Dicay M, McKnight W, Dudar GK,. Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor. Br J Pharmacol 2006; 148: 274 - 8.
35. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B,. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435 - 42.
36. Wägner A, Montero D, Mårtensson B, et al. Effects of fluoxetine treatment of platelet H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Disord 1990; 20: 101 - 13.
37. Moride Y, Abenhaim L,. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731 - 7.
38. De Abajo FJ, Montero D, Rodríguez LA, Madurga M,. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304 - 10.